Novel treatments for metastatic renal cell carcinoma

Critical Reviews in Oncology/Hematology

Volumn 55, Issue 3, 2005, Pages 177-191

  Van Spronsen, D J ^a   Mulders, P F A ^a   De Mulder, P H M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Metastatic; Novel treatments; Renal cell carcinoma; Systemic therapy; Targeted drugs

Indexed keywords

ACETYLCYSTEINE; AE 941; ALPHA INTERFERON; BEVACIZUMAB; CIMETIDINE; CYCLOPHOSPHAMIDE; CYTOKINE; EPIRUBICIN; ERLOTINIB; FLOXURIDINE; FLUOROURACIL; HEAT SHOCK PROTEIN 90; IFOSFAMIDE; INFLIXIMAB; INTERLEUKIN 2; INTERLEUKIN 6 ANTIBODY; ISOTRETINOIN; LAPATINIB; MELATONIN; MITOMYCIN; MONOCLONAL ANTIBODY G250; RAF PROTEIN; SORAFENIB; SUNITINIB; TEMSIROLIMUS; THALIDOMIDE; UNINDEXED DRUG; VASCULOTROPIN; VATALANIB; VINBLASTINE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ALLOGENEIC STEM CELL TRANSPLANTATION; ANEMIA; ANGIOGENESIS; ANOREXIA; ANTIANGIOGENIC ACTIVITY; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER SURGERY; CANCER SURVIVAL; CHEMOTHERAPY; CHILL; CLINICAL TRIAL; CONSTIPATION; DENDRITIC CELL; DEPRESSION; DIARRHEA; DYSPEPSIA; ESTROGEN THERAPY; FATIGUE; FEVER; HAND FOOT SYNDROME; HEADACHE; HORMONAL THERAPY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPERTHYROIDISM; HYPOTENSION; IMMUNOTHERAPY; KIDNEY CARCINOMA; KIDNEY METASTASIS; LETHARGY; LEUKOPENIA; LYMPHOCYTOPENIA; MOLECULAR BIOLOGY; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; NEPHRECTOMY; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; OLIGURIA; PERFORMANCE; PROTEINURIA; RASH; SUPPRESSOR GENE; SURVIVAL RATE; THROMBOCYTOPENIA; THROMBOEMBOLISM; VOMITING; VON HIPPEL LINDAU DISEASE;

EID: 24044549635     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2005.04.002     Document Type: Review

References (154)

1. www.seer.cancer.gov, 2004.
2. P.H.M. De Mulder, C.M.L. van Herpen, and P.A.F. Mulders Current treatment of renal cell carcinoma Ann Oncol 15S 2004 319 328
3. R.T. Oliver, A.B. Nethersell, and J.M. Bottomley Unexplained spontaneous regression and alpha-interferon as treatment for metastatic renal carcinoma Br J Urol 63 1989 128 131
4. J. Atzpodien, H. Kirchner, and H.J. Illiger IL-2 in combination with IFN-alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial Br J Cancer 85 2001 1130 1136
5. R.J. Motzer, N.H. Bander, and D.M. Nanus Renal-cell carcinoma N Engl J Med 335 1996 865 875
6. R.J. Motzer, and P. Russo Systemic therapy for renal cell carcinoma J Urol 163 2000 408 417
7. A. Yagoda, B. Abi-Rached, and D. Petrylak Chemotherapy for advanced renal-cell carcinoma: 1983-1993 Semin Oncol 22 1995 42 60
8. W.M. Stadler, D. Huo, and C. George Prognostic factors for survival with gemcitabine plus 5-fluorouracil based regimens for metastatic renal cancer J Urol 170 2003 1141 1145
9. R.C. Flanigan, G. Mickisch, R. Sylvester, C. Tangen, H. van Poppel, and E.D. Crawford Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis J Urol 171 2004 1071 1076
10. G.H. Mickisch, A. Garin, H. van Poppel, L. de Prijck, and R. Sylvester Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial Lancet 358 2001 966 970
11. R.C. Flanigan, S.E. Salmon, and B.A. Blumenstein Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer N Engl J Med 345 2001 1655 1659
12. J.P. Kavolius, D.P. Mastorakos, C. Pavlovich, P. Russo, M.E. Burt, and M.S. Brady Resection of metastatic renal cell carcinoma J Clin Oncol 16 1998 2261 2266
13. S.H. Goey, J. Verweij, and G. Stoter Immunotherapy of metastatic renal cell cancer Ann Oncol 7 1996 887 900
14. W.G. Kaelin Kidney cancer: lessons from von Hippel-Lindau disease 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition) J Clin Oncol 22 July (Suppl. 14S) 2004
15. S. Pyrhonen, E. Salminen, and M. Ruutu Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer J Clin Oncol 17 1999 2859 2867
16. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators. Lancet 1999;353:14-7.
17. J.M. Kirkwood, J.E. Harris, and R. Vera A randomized study of low and high doses of leukocyte alpha-interferon in metastatic renal cell carcinoma: the American Cancer Society collaborative trial Cancer Res 45 1985 863 871
18. T. Umeda, and T. Niijima Phase II study of alpha interferon on renal cell carcinoma. Summary of three collaborative trials Cancer 58 1986 1231 1235
19. J.R. Quesada, A. Rios, D. Swanson, P. Trown, and J.U. Gutterman Antitumor activity of recombinant-derived interferon alpha in metastatic renal cell carcinoma J Clin Oncol 3 1985 1522 1528
20. P.H. de Mulder, G. Oosterhof, C. Bouffioux, A.T. van Oosterom, K. Vermeylen, and R. Sylvester EORTC (30885) randomised phase III study with recombinant interferon alpha and recombinant interferon alpha and gamma in patients with advanced renal cell carcinoma. The EORTC Genitourinary Group Br J Cancer 71 1995 371 375
21. R.J. Motzer, A. Rakhit, and J. Thompson Phase II trial of branched peginterferon-alpha 2a (40 kDa) for patients with advanced renal cell carcinoma Ann Oncol 13 2002 1799 1805
22. R. Bukowski, M.S. Ernstoff, and M.E. Gore Pegylated interferon alfa-2b treatment for patients with solid tumors: a phase I/II study J Clin Oncol 20 2002 3841 3849
23. S.A. Rosenberg, M.T. Lotze, and L.M. Muul Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer N Engl J Med 313 1985 1485 1492
24. S.A. Rosenberg, J.C. Yang, and S.L. Topalian Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2 JAMA 271 1994 907 913
25. G. Fyfe, R.I. Fisher, S.A. Rosenberg, M. Sznol, D.R. Parkinson, and A.C. Louie Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy J Clin Oncol 13 1995 688 696
26. J.C. Yang, R.M. Sherry, and S.M. Steinberg Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer J Clin Oncol 21 2003 3127 3132
27. W.H. West, K.W. Tauer, and J.R. Yannelli Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer N Engl J Med 316 1987 898 905
28. M.E. Gore, E. Galligioni, and C.W. Keen The treatment of metastatic renal cell carcinoma by continuous intravenous infusion of recombinant interleukin-2 Eur J Cancer 30A 1994 329 333
29. M. Jones, T. Philip, and P. Palmer The impact of interleukin-2 on survival in renal cancer: a multivariate analysis Cancer Biother 8 1993 275 288
30. D.T. Sleijfer, R.A. Janssen, J. Buter, E.G. de Vries, P.H. Willemse, and N.H. Mulder Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis J Clin Oncol 10 1992 1119 1123
31. S. Negrier, B. Escudier, and C. Lasset Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie N Engl J Med 338 1998 1272 1278
32. P.F. Geertsen, M.E. Gore, S. Negrier, J.M. Tourani, and M.H. von der Safety and efficacy of subcutaneous and continuous intravenous infusion rIL-2 in patients with metastatic renal cell carcinoma Br J Cancer 90 2004 1156 1162
33. D.F. McDermott, M.M. Regan, and J.I. Clark Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma J Clin Oncol 23 2005 133 141
34. J. Atzpodien, H.E. Lopez, and H. Kirchner Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma J Clin Oncol 13 1995 497 501
35. A. Ravaud, S. Negrier, and L. Cany Subcutaneous low-dose recombinant interleukin 2 and alpha-interferon in patients with metastatic renal cell carcinoma Br J Cancer 69 1994 1111 1114
36. D.H. Ilson, R.J. Motzer, and R.L. Kradin A phase II trial of interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma J Clin Oncol 10 1992 1124 1130
37. N.J. Vogelzang, A. Lipton, and R.A. Figlin Subcutaneous interleukin-2 plus interferon alfa-2a in metastatic renal cancer: an outpatient multicenter trial J Clin Oncol 11 1993 1809 1816
38. J.M. Tourani, C. Pfister, and N. Tubiana Subcutaneous interleukin-2 and interferon alfa administration in patients with metastatic renal cell carcinoma: final results of SCAPP III, a large, multicenter, phase II, nonrandomized study with sequential analysis design - the Subcutaneous Administration Propeukin Program Cooperative Group J Clin Oncol 21 2003 3987 3994
39. J.I. Clark, T.M. Kuzel, and T.M. Lestingi A multi-institutional phase II trial of a novel inpatient schedule of continuous interleukin-2 with interferon alpha-2b in advanced renal cell carcinoma: major durable responses in a less highly selected patient population Ann Oncol 13 2002 606 613
40. N. Verra, R. Jansen, and G. Groenewegen Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-alpha in patients with progressive metastatic renal cell carcinoma Br J Cancer 88 2003 1346 1351
41. B. Escudier, C. Chevreau, and C. Lasset Cytokines in metastatic renal cell carcinoma: is it useful to switch to interleukin-2 or interferon after failure of a first treatment? Groupe Francais d'Immunotherape J Clin Oncol 17 1999 2039 2043
42. S. Wadler, A.I. Einzig, J.P. Dutcher, N. Ciobanu, L. Landau, and P.H. Wiernik Phase II trial of recombinant alpha-2b-interferon and low-dose cyclophosphamide in advanced melanoma and renal cell carcinoma Am J Clin Oncol 11 1988 55 59
43. A. Panetta, A. Martoni, and M. Guaraldi Combined chemo-immuno- hormonotherapy of advanced renal cell carcinoma J Chemother 6 1994 349 353
44. A. Falcone, C. Cianci, and E. Pfanner Treatment of metastatic renal cell carcinoma with constant-rate floxuridine infusion plus recombinant alpha 2b-interferon Ann Oncol 7 1996 601 605
45. A. Sella, C.J. Logothetis, and K. Fitz Phase II study of interferon-alpha and chemotherapy (5-fluorouracil and mitomycin C) in metastatic renal cell cancer J Urol 147 1992 573 577
46. J. Atzpodien, H. Kirchner, E.L. Hanninen, M. Deckert, M. Fenner, and H. Poliwoda Interleukin-2 in combination with interferon-alpha and 5-fluorouracil for metastatic renal cell cancer Eur J Cancer 29A Suppl. 5 1993 6S 8S
47. J. Atzpodien, H. Kirchner, and U. Jonas Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a prospectively randomized trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN) J Clin Oncol 22 2004 1188 1194
48. G. Hofmockel, W. Langer, M. Theiss, A. Gruss, and H.G. Frohmuller Immunochemotherapy for metastatic renal cell carcinoma using a regimen of interleukin-2, interferon-alpha and 5-fluorouracil J Urol 156 1996 18 21
49. J.K. Joffe, R.E. Banks, and M.A. Forbes A phase II study of interferon-alpha, interleukin-2 and 5-fluorouracil in advanced renal carcinoma: clinical data and laboratory evidence of protease activation Br J Urol 77 1996 638 649
50. J.P. Dutcher, T. Logan, and M. Gordon Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study Clin Cancer Res 6 2000 3442 3450
51. C.M. van Herpen, R.L. Jansen, and W.H. Kruit Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study Dutch Immunotherapy Working Party Br J Cancer 82 2000 772 776
52. J.A. Ellerhorst, A. Sella, and R.J. Amato Phase II trial of 5-fluorouracil, interferon-alpha and continuous infusion interleukin-2 for patients with metastatic renal cell carcinoma Cancer 80 1997 2128 2132
53. J.M. Tourani, C. Pfister, and J.F. Berdah Outpatient treatment with subcutaneous interleukin-2 and interferon alfa administration in combination with fluorouracil in patients with metastatic renal cell carcinoma: results of a sequential nonrandomized phase II study. Subcutaneous Administration Propeukin Program Cooperative Group J Clin Oncol 16 1998 2505 2513
54. S.D. Fossa, G.H. Mickisch, and P.H. de Mulder Interferon-alpha-2a with or without 13-cis retinoic acid in patients with progressive, measurable metastatic renal cell carcinoma Cancer 101 2004 533 540
55. N. Aass, P.H.M. De Mulder, and G.H.J. Mickisch Interferon alpha-2a with and without 13-cis retinoic acid in patients with progressive metastatic renal cell carcinoma. A randomised phase II/III trial (EORTC 30951) J Clin Oncol 2005
56. R.J. Motzer, B.A. Murphy, and J. Bacik Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma J Clin Oncol 18 2000 2972 2980
57. T. Kinouchi, S. Saiki, O. Maeda, M. Kuroda, M. Usami, and T. Kotake Treatment of advanced renal cell carcinoma with a combination of human lymphoblastoid interferon-alpha and cimetidine J Urol 157 1997 1604 1607
58. E.T. Creagan, J.C. Buckner, R.G. Hahn, R.R. Richardson, D.J. Schaid, and J.S. Kovach An evaluation of recombinant leukocyte A interferon with aspirin in patients with metastatic renal cell cancer Cancer 61 1988 1787 1791
59. W.C. Mertens, V.H. Bramwell, and D. Banerjee Sustained oral indomethacin and ranitidine with intermittent continuous infusion interleukin-2 in advanced renal cell carcinoma Cancer Biother 8 1993 229 233
60. A. Belldegrun, W. Pierce, and R. Kaboo Interferon-alpha primed tumor-infiltrating lymphocytes combined with interleukin-2 and interferon-alpha as therapy for metastatic renal cell carcinoma J Urol 150 1993 1384 1390
61. K. Margolin, F.R. Aronson, and M. Sznol Phase II studies of recombinant human interleukin-4 in advanced renal cancer and malignant melanoma J Immunother Emphasis Tumor Immunol 15 1994 147 153
62. M.B. Atkins, M.J. Robertson, and M. Gordon Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies Clin Cancer Res 3 1997 409 417
63. R.P. Whitehead, D. Lew, and R.C. Flanigan Phase II trial of recombinant human interleukin-4 in patients with advanced renal cell carcinoma: a southwest oncology group study J Immunother 25 2002 352 358
64. B.I. Rini, W.M. Stadler, R.T. Spielberger, M.J. Ratain, and N.J. Vogelzang Granulocyte-macrophage - colony stimulating factor in metastatic renal cell carcinoma: a phase II trial Cancer 82 1998 1352 1358
65. J.A. Gollob, K.G. Veenstra, and R.A. Parker Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma J Clin Oncol 21 2003 2564 2573
66. R.J. Motzer, A. Rakhit, and J.A. Thompson Randomized multicenter phase II trial of subcutaneous recombinant human interleukin-12 versus interferon-alpha 2a for patients with advanced renal cell carcinoma J Interferon Cytokine Res 21 2001 257 263
67. G.C. de Gast, H.J. Klumpen, and F.A. Vyth-Dreese Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma Clin Cancer Res 6 2000 1267 1272
68. J.C. Oosterwijk-Wakka, D.M. Tiemessen, and I. Bleumer Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: a phase 1 study J Immunother 25 2002 500 508
69. L. Holtl, C. Zelle-Rieser, and H. Gander Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells Clin Cancer Res 8 2002 3369 3376
70. A. Marten, D. Flieger, and S. Renoth Therapeutic vaccination against metastatic renal cell carcinoma by autologous dendritic cells: preclinical results and outcome of a first clinical phase I/II trial Cancer Immunol Immunother 51 2002 637 644
71. A. Marten, S. Renoth, and T. Heinicke Allogeneic dendritic cells fused with tumor cells: preclinical results and outcome of a clinical phase I/II trial in patients with metastatic renal cell carcinoma Hum Gene Ther 14 2003 483 494
72. D. Avigan, B. Vasir, and J. Gong Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses Clin Cancer Res 10 2004 4699 4708
73. D. Avigan Dendritic cell-tumor fusion vaccines for renal cell carcinoma Clin Cancer Res 10 2004 6347S 6352S
74. K. Grabmaier, J.L. Vissers, and M.C. De Weijert Molecular cloning and immunogenicity of renal cell carcinoma-associated antigen G250 Int J Cancer 85 2000 865 870
75. J.L. Vissers, I.J. de Vries, and L.P. Engelen Renal cell carcinoma-associated antigen G250 encodes a naturally processed epitope presented by human leukocyte antigen-DR molecules to CD4(+) T lymphocytes Int J Cancer 100 2002 441 444
76. R. Childs, A. Chernoff, and N. Contentin Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation N Engl J Med 343 2000 750 758
77. B.I. Rini, T. Zimmerman, W.M. Stadler, T.F. Gajewski, and N.J. Vogelzang Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results J Clin Oncol 20 2002 2017 2024
78. P. Pedrazzoli, G.A. Da Prada, and G. Giorgiani Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies Cancer 94 2002 2409 2415
79. M. Bregni, A. Dodero, and J. Peccatori Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer Blood 99 2002 4234 4236
80. P. Hentschke, L. Barkholt, and M. Uzunel Low-intensity conditioning and hematopoietic stem cell transplantation in patients with renal and colon carcinoma Bone Marrow Transplant 31 2003 253 261
81. N.T. Ueno, Y.C. Cheng, and G. Rondon Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors Blood 102 2003 3829 3836
82. Y. Takahashi, and R.W. Childs Nonmyeloablative transplantation: an allogeneic-based immunotherapy for renal cell carcinoma Clin Cancer Res 10 2004 6353S 6359S
83. N. Schaap, A. Schattenberg, and B. Bar Induction of graft-versus-leukemia to prevent relapse after partially lymphocyte-depleted allogeneic bone marrow transplantation by pre-emptive donor leukocyte infusions Leukemia 15 2001 1339 1346
84. M.G. Steffens, O.C. Boerman, and P.H. de Mulder Phase I radioimmunotherapy of metastatic renal cell carcinoma with 131I-labeled chimeric monoclonal antibody G250 Clin Cancer Res 5 1999 3268s 3274s
85. A.H. Brouwers, W.C. Buijs, and E. Oosterwijk Targeting of metastatic renal cell carcinoma with the chimeric monoclonal antibody G250 labeled with (131)I or (111)In: an intrapatient comparison Clin Cancer Res 9 2003 3953S 3960S
86. Z. Varga, P. De Mulder, and W. Kruit A prospective open-label single-arm phase II study of chimeric monoclonal antibody cG250 in advanced renal cell carcinoma patients Folia Biol (Praha) 49 2003 74 77
87. I. Bleumer, A. Knuth, and E. Oosterwijk A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients Br J Cancer 90 2004 985 990
88. M. Trikha, R. Corringham, B. Klein, and J.F. Rossi Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence Clin Cancer Res 9 2003 4653 4665
89. S. Negrier, D. Perol, and C. Menetrier-Caux Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6 - from the Groupe Francais d'Immunotherapie J Clin Oncol 22 2004 2371 2378
90. J.Y. Blay, J.F. Rossi, and J. Wijdenes Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma Int J Cancer 72 1997 424 430
91. A. Klinkhoff Biological agents for rheumatoid arthritis: targeting both physical function and structural damage Drugs 64 2004 1267 1283
92. N.R. Maisey, K. Hall, C. Lee, E. Timotheadou, R. Ahern, and T.M. Eisen Gore Infliximab: a phase II trial of the tumour necrosis factor (TNFa) monoclonal antibody in patients with advanced renal cell cancer (RCC) 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition) J Clin Oncol 22 July (Suppl. 14S) 2004 4514
93. P.K. Srivastava Immunotherapy for human cancer using heat shock protein-peptide complexes Curr Oncol Rep 7 2005 104 108
94. C.G. Wood, B. Escudier, and S. Gorelov A multicenter randomized study of adjuvant heat-shock protein peptide-complex 96 (HSPPC-96) vaccine in patients with high-risk of recurrence after nephrectomy for renal cell carcinoma (RCC) - a preliminary report ASCO Annual Meeting Proceedings (Post-Meeting Edition) J Clin Oncol 22 2004 2618
95. B.I. Rini, and E.J. Small Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma J Clin Oncol 23 5 2005 1028 1043
96. J.R. Gnarra, S. Zhou, and M.J. Merrill Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene Proc Natl Acad Sci USA 93 1996 10589 10594
97. K.J. Turner, J.W. Moore, and A. Jones Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation Cancer Res 62 2002 2957 2961
98. M.S. Wiesener, P.M. Munchenhagen, and I. Berger Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas Cancer Res 61 2001 5215 5222
99. T. Massfelder, H. Lang, and E. Schordan Parathyroid hormone-related protein is an essential growth factor for human clear cell renal carcinoma and a target for the von Hippel-Lindau tumor suppressor gene Cancer Res 64 2004 180 188
100. K. Grabmaier, MC.Ad Weijert, G.W. Verhaegh, J.A. Schalken, and E. Oosterwijk Strict regulation of CAIX(G250/MN) by HIF-1alpha in clear cell renal cell carcinoma Oncogene 23 2004 5624 5631
101. X. Na, G. Wu, C.K. Ryan, S.R. Schoen, P.A. di'Santagnese, and E.M. Messing Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas J Urol 170 2003 588 592
102. B.I. Rini, and E.J. Small Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma J Clin Oncol 23 2005
103. B. Knebelmann, S. Ananth, H.T. Cohen, and V.P. Sukhatme Transforming growth factor alpha is a target for the von Hippel-Lindau tumor suppressor Cancer Res 58 1998 226 231
104. E.R. Sargent, L.G. Gomella, A. Belldegrun, W.M. Linehan, and A. Kasid Epidermal growth factor receptor gene expression in normal human kidney and renal cell carcinoma J Urol 142 1989 1364 1368
105. H.F. Dvorak Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy J Clin Oncol 20 2002 4368 4380
106. F.A. Scappaticci Mechanisms and future directions for angiogenesis-based cancer therapies J Clin Oncol 20 2002 3906 3927
107. R.J. Amato Thalidomide therapy for renal cell carcinoma Crit Rev Oncol Hematol 46 Suppl. 2003 59 65
108. T. Eisen Phase II results of a phase II/III study comparing thalidomide with medroxyprogesterone in patients with metastatic renal cell carcinoma Proc Am Soc Clin Oncol 22 2003 400 abstract 1606
109. R.J. Amato, J. Schell, N. Thompson, R. Moore, and B. Miles Phase II study of thalidomide + interleukin-2 (il-2) in patients with metastatic renal cell carcinoma (MRCC0) Proc Am Soc Clin Oncol 22 2003 387 (abstract 1556)
110. A. Sella, C. Sternberg, and N. Yarom Phase II study of low dose thalidomide and interferon-alfa in metastatic renal cell carcinoma (RCC) Proc Am Soc Clin Oncol 22 2003 402 [abstract 1614]
111. M.S. Gordon, J. Manola, and D. Fairclough Low dose interferon-á2b (IFN) + thalidomide (T) in patients (pts) with previously untreated renal cell cancer (RCC). Improvement in progression-free survival (PFS) but not quality of life (QoL) or overall survival (OS). A phase III study of the Eastern Cooperative Oncology Group (E2898) ASCO Annual Meeting Proceedings (Post-Meeting Edition) J Clin Oncol 22 July (Suppl. 14S) 2004 4516
112. G. Batist, F. Patenaude, and P. Champagne Neovastat (AE-941) in refractory renal cell carcinoma patients: report of a phase II trial with two dose levels Ann Oncol 13 2002 1259 1263
113. G. Batist, P. Champagne, C. Hariton, and E. Dupont Dose-survival relationship in a phase II study of neovastat in refractory renal cell carcinoma patients Proc Am Soc Clin Oncol 2002 [abstract 1907]
114. B. Escudier, P. Venner, and R. Buckowski Phase III trial of Neovastat in metastatic renal cell carcinoma patients refractory to immunotherapy. Proc Am Soc Clin Oncol 22 2003 211 (abstract 844)
115. B. Escudier, P. Venner, and L. Stern Prognostic factors in metastatic renal cell carcinoma after failure of immunotherapy: lessons from a large phase III trial ASCO Annual Meeting Proceedings (Post-Meeting Edition) J Clin Oncol 22 July (Suppl. 14S) 2004 4547
116. J.C. Yang, L. Haworth, and R.M. Sherry A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer N Engl J Med 349 2003 427 434
117. B.I. Rini, S. Halabi, J. Taylor, E.J. Small, and R.L. Schilsky Cancer and Leukemia Group B 90206: a randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma Clin Cancer Res 10 2004 2584 2586
118. A. Sistla, A. Sunga, K. Phung, A. Koparkar, and N. Shenoy Powder-in-bottle formulation of SU011248. Enabling rapid progression into human clinical trials Drug Dev Ind Pharm 30 2004 19 25
119. D.B. Mendel, A.D. Laird, and X. Xin In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship Clin Cancer Res 9 2003 327 337
120. L. Sun, C. Liang, and S. Shirazian Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase J Med Chem 46 2003 1116 1119
121. A.M. O'Farrell, T.J. Abrams, and H.A. Yuen SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo Blood 101 2003 3597 3605
122. R.J. Motzer, B.I. Rini, and M.D. Michaelson SU011248, a novel tyrosine kinase inhibitor, shows antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma: results of a phase 2 trial ASCO Annual Meeting Proceedings (Post-Meeting Edition) J Clin Oncol 22 July (Suppl. 14S) 2004 4500
123. R.S. Tuma Three molecularly targeted drugs tested in kidney cancer clinical trials J Natl Cancer Inst 96 2004 1270 1271
124. J.M. Wood, G. Bold, and E. Buchdunger PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration Cancer Res 60 2000 2178 2189
125. D. George, D. Michaelson, and W.K. Oh Phase I study of PTK787/ZK 222584 (PTK/ZK) in metastatic renal cell carcinoma Proc Am Soc Clin Oncol 22 2003 385 abstract 1548
126. F. Chang, L.S. Steelman, and J.T. Lee Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention Leukemia 17 2003 1263 1293
127. F. Chang, J.T. Lee, and P.M. Navolanic Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy Leukemia 17 2003 590 603
128. G.M. Higa Targeted therapies in oncology: in the crosshairs or at the crossroads? Expert Rev Anticancer Ther 4 2004 61 75
129. Y. Takai, T. Sasaki, and T. Matozaki Small GTP-binding proteins Physiol Rev 81 2001 153 208
130. J. Avruch, A. Khokhlatchev, and J.M. Kyriakis Ras activation of the Raf kinase: tyrosine kinase recruitment of the MAP kinase cascade Recent Prog Horm Res 56 2001 127 155
131. G. Bollag, S. Freeman, J.F. Lyons, and L.E. Post Raf pathway inhibitors in oncology Curr Opin Investig Drugs 4 2003 1436 1441
132. G. Bollag, S. Freeman, J.F. Lyons, and L.E. Post Raf pathway inhibitors in oncology Curr Opin Investig Drugs 4 2003 1436 1441
133. S. Wilhelm, and D.S. Chien BAY 43-9006: preclinical data Curr Pharm Des 8 2002 2255 2257
134. D. Strumberg, D. Voliotis, and J.G. Moeller Results of phase I pharmacokinetic and pharmacodynamic studies of the Raf kinase inhibitor BAY 43-9006 in patients with solid tumors Int J Clin Pharmacol Ther 40 2002 580 581
135. T. Ahmad, and T. Eisen Kinase inhibition with BAY 43-9006 in renal cell carcinoma Clin Cancer Res 10 2004 6388 6392
136. M.J. Ratain, K.T. Flaherty, and W.M. Stadler Preliminary antitumor activity of BAY 43-9006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a phase II randomized discontinuation trial (RDT) ASCO Annual Meeting Proceedings (Post-Meeting Edition) J Clin Oncol 22 July (Suppl. 14S) 2004 4500
137. J.P. Dutcher Mammalian target of rapamycin inhibition Clin Cancer Res 10 2004 6382 6387
138. S. Chan Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer Br J Cancer 91 2004 1420 1424
139. C.C. Hudson, M. Liu, and G.G. Chiang Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin Mol Cell Biol 22 2002 7004 7014
140. A. Panwalkar, S. Verstovsek, and F.J. Giles Mammalian target of rapamycin inhibition as therapy for hematologic malignancies Cancer 100 2004 657 666
141. E. Raymond, J. Alexandre, and S. Faivre Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer J Clin Oncol 22 2004 2336 2347
142. M.B. Atkins, M. Hidalgo, and W.M. Stadler Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma J Clin Oncol 22 2004 909 918
143. M. Hidalgo, M.B. Atkins, and W.M. Stadler A randomized double-blind phase 2 study of intravenous (IV) CCI-779 administerd weekly to patients with advanced renal cell carcinoma RCC: prognostic factor analyis. Proc Am Soc Clin Oncol 22 2003 201 [abstract 804]
144. M.B. Atkins, M. Hidalgo, W. Stadler, T. Logan, J.P. Dutcher, and G. Hudes A randomized double-blind phase 2 study of intravenous CCI-779 administered weekly to patients with advanced renal cell carcinoma Proc Am Soc Clin Oncol 2002 [abstract 36]
145. J.P. Dutcher, G. Hudes, and R. Motzer Preliminary report of a phase 1 study of intravenous (iv) CCI-779 given in combination with interferon-a (IFN) to patietns wiht advanced renal cell carcinoma (RCC) Proc Am Soc Clin Oncol 22 2003 213 [abstract 854]
146. J.W. Smith, Y.-J. Ko, and J. Dutcher Update of a phase 1 study of intravenous CCI-779 given in combination with interferon-a to patients with advanced renal cell carcinoma ASCO Annual Meeting Proceedings (Post-Meeting Edition) J Clin Oncol 22 July (Suppl. 14S) 2004 4513
147. R.J. Motzer, R. Amato, and M. Todd Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma Invest New Drugs 21 2003 99 101
148. G. Schwartz, J.P. Dutcher, and N.J. Vogelzang Phase 2 clinical trial evaluating the safety and effectiveness of ABX-EGF in renal cell cancer (RCC) Proc Am Soc Clin Oncol 2002 (abstract 91)
149. B. Drucker, J. Bacik, and M. Ginsberg Phase II trial of ZD1839 (IRESSA) in patients with advanced renal cell carcinoma Invest New Drugs 21 2003 341 345
150. E.R. Wood, A.T. Truesdale, and O.B. McDonald A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells Cancer Res 64 2004 6652 6659
151. H.A. Burris III Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib Oncologist 9 Suppl. 3 2004 10 15
152. J.D. Hainsworth, J.A. Sosman, and D.R. Spigel Phase II trial of bevacizumab and erlotinib in patients with metastatic renal carcinoma (RCC) ASCO Annual Meeting Proceedings (Post-Meeting Edition) J Clin Oncol 22 July (Suppl. 14S) 2004 4502
153. W.R. Parulekar, and E.A. Eisenhauer Novel endpoints and design of early clinical trials Ann Oncol 13 Suppl. 4 2002 139 143
154. G. Giaccone, R.S. Herbst, and C. Manegold Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 1 J Clin Oncol 22 2004 777 784